Edition:
United Kingdom

Correvio Pharma Corp (CORV.OQ)

CORV.OQ on NASDAQ Stock Exchange Capital Market

3.20USD
16 Nov 2018
Change (% chg)

$0.06 (+1.91%)
Prev Close
$3.14
Open
$3.16
Day's High
$3.23
Day's Low
$3.15
Volume
9,474
Avg. Vol
29,854
52-wk High
$5.23
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Correvio Announces Brinavess Eligibility For Patent Extension
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES BRINAVESS ELIGIBILITY FOR PATENT EXTENSION.CORREVIO PHARMA - RECEIVED INDEPENDENT REGULATORY AND LEGAL OPINIONS THAT BRINAVESS MAY QUALIFY FOR UP TO 5-YEAR PATENT EXTENSION FROM USPTO.CORREVIO PHARMA CORP - WILL BE RESUBMITTING A NEW DRUG APPLICATION (NDA) FOR BRINAVESS TO FDA DURING Q2 OF 2019.  Full Article

Correvio Announces Intention To Re-File Brinavess NDA In Q2 2019
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Correvio Pharma Corp ::CORREVIO ANNOUNCES INTENTION TO RE-FILE BRINAVESS NDA IN SECOND QUARTER 2019.CORREVIO PHARMA CORP - PLANS TO RESUBMIT BRINAVESS (VERNAKALANT HYDROCHLORIDE, IV) NEW DRUG APPLICATION (NDA) DURING Q2 OF 2019.CORREVIO PHARMA CORP - NO ADDITIONAL STUDIES REQUIRED FOR RESUBMISSION.  Full Article

Correvio Q1 Loss Per Share $0.24
Tuesday, 15 May 2018 

May 15 (Reuters) - Cardiome Pharma Corp ::CORREVIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $6.5 MILLION VERSUS I/B/E/S VIEW $5.9 MILLION.Q1 LOSS PER SHARE $0.24.Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.CORREVIO PHARMA CORP - AT MARCH 31, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS OF $13.6 MILLION.  Full Article

Cardiome Announces Amendment To Term Loan Agreement With CRG Managed Funds
Friday, 6 Apr 2018 

April 6 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES AMENDMENT TO TERM LOAN AGREEMENT WITH CRG-MANAGED FUNDS.ENTERED INTO FIRST AMENDING AGREEMENT TO ITS MAY 11, 2017 AMENDED & RESTATED TERM LOAN AGREEMENT WITH CRG SERVICING LLC MANAGED FUNDS.CRG HAS WAIVED ITS RIGHT TO RECEIVE PAYMENT OF CERTAIN CASH COMPENSATION OF UP TO $6 MILLION DOLLARS.IN CONSIDERATION FOR ENTERING AMENDED AGREEMENT, CRG RECEIVED 800,000 COMMON SHARE PURCHASE WARRANTS WITH $2.50 EXERCISE PRICE.  Full Article

Cardiome Announces Expanded Label For Aggrastat In China
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES EXPANDED LABEL FOR AGGRASTAT® IN CHINA INCLUDING NEW STEMI INDICATION AND HIGH DOSE BOLUS REGIMEN.CARDIOME PHARMA - AGGRASTAT EXPANDED LABEL NOW INCLUDE PATIENTS WITH STEMI WHO ARE INTENDED FOR PRIMARY PERCUTANEOUS CORONARY INTERVENTION.CARDIOME PHARMA - CHINESE CENTER FOR DRUG EVALUATION ALSO APPROVED AGGRASTAT HIGH DOSE BOLUS REGIMEN TO BE USED ON BOTH INDICATED PATIENT POPULATIONS IN STUDY.  Full Article

Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA.CARDIOME PHARMA CORP - AFFILIATE CORREVIO HAS ENTERED INTO AN EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT WITH ZAO FIRMA EUROSERVICE.CARDIOME PHARMA - AS PER LICENSE AGREEMENT, ZAO WILL BE RESPONSIBLE FOR OBTAINING REGULATORY APPROVALS FOR AGGRASTAT FROM RUSSIA'S MINISTRY OF HEALTH.CARDIOME PHARMA CORP - ADDITIONAL TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Cardiome Q3 loss per share $0.20
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Cardiome Pharma Corp :Cardiome reports third quarter 2017 financial results.Sees fy 2017 revenue $24 million to $26 million.Q3 revenue $6.0 million versus I/B/E/S view $7.3 million.Q3 loss per share $0.20.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.Cardiome Pharma Corp - expects existing cash and cash equivalents will be sufficient to fund its operations for at least next 12 months..  Full Article

Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Cardiome Pharma Corp -:Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​.  Full Article